A bill for an act relating to the right to try Act.

Added a new category of eligible patients who have life-threatening or severely debilitating illnesses, not just terminal illnesses.

Required patients with life-threatening conditions to have exhausted treatment options through contraindication, potential or previous treatment failure, or actual or potential adverse reaction.

Expanded the definition of investigational treatments to include individualized therapies based on genomic sequence, chromosomes, DNA, RNA, genes, gene products, or metabolites.

Added specific requirements for informed consent documentation when patients seek individualized investigational treatments based on genomic analysis.

Updated informed consent requirements to include clearer identification of specific proposed individualized investigational treatments for genomic-based therapies.

Formatting and signature corrections were made to the Governor's transmittal letter, including fixing a typo in the closing signature from 'Sincgely' to 'Sincerely' and correcting the name signature from 'nolds' to 'Reynolds'.

Page numbering and section headers were standardized to match the enrolled version format, with line numbers added for legislative tracking purposes.